⚕ GalenOps field
←

SITE014-0137

withdrawn

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2022-08-09

AEs
8
Serious
0
Dropout signal
–

Adverse events

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-09-09 (study day 23); relationship: N

mild assessed

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-02-11 (study day 178); relationship: N

severe assessed

Grade 3 Alopecia — outcome: UNKNOWN; onset 2023-02-28 (study day 195); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-04-19 (study day 245); relationship: N

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-12-08 (study day 478); relationship: not assessed

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-12-18 (study day 488); relationship: N

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-01-14 (study day 515); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-02-28 (study day 560); relationship: N

Data queries

No data queries.